Optimized stent for high bleeding risk patients
Part of Heart & circulation clinical trials.
This trial tests a special stent designed for people who have a high risk of bleeding. It aims to see if using this stent with a shorter treatment of blood thinners can be safe and effective for heart artery procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You need a heart artery procedure (angioplasty) to open blocked vessels.
- Your doctor has chosen to use the HT-supreme stent for your procedure.
- You have a high risk of bleeding based on medical guidelines.
- You are covered by a social security system.
- You agree to participate and do not object to the research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a specific stent (with no polymer coating) plus a single blood thinner plan with aspirin and another P2Y12 medicine is as safe and effective as the standard two-medicine plan after a STEMI heart attack. It may help people avoid longer exposure to stronger blood-thinning if the new approach works as well.
This trial tests ways to improve safety for people with high bleeding risk who take blood thinners after getting a heart stent. It aims to find better quality checks to prevent bleeding and clotting problems.
This trial tests if a shorter, lower dose of two blood thinners is safe and effective for patients with a recent heart attack or unstable angina who are at high risk for bleeding. It uses a special stent that might allow for less medication.
This trial tests a new type of stent (BioFreedom Ultra) compared to a standard one (BioFreedom) in people who have a high risk of bleeding. Both stents release medicine to keep arteries open, and the study checks if the newer stent works better with a shorter course of blood thinners.
This trial studies ways to reduce bleeding in people after a stent procedure (PCI) who have been taking two anti-platelet medicines (aspirin plus prasugrel or ticagrelor) for a set amount of time. It may help find a safer plan for preventing blood clots while lowering bleeding risk.
This trial tests a shorter course of dual antiplatelet therapy (aspirin plus ticagrelor) after stent placement, switching early to just ticagrelor alone. It aims to see if this approach can safely reduce bleeding risks while still protecting against heart problems in people with stable coronary artery disease.
Hear when a new Cardiology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.